未登录

V

Victor Sokolov

Modeling and Simulation Decisions FZ LLC

H指数:16

被引数:770

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Bayesian Workflow for Minimal PBPK Models: Case Study of Dapagliflozin

贝叶斯工作流程在最小PBPK模型中的应用：达格列净案例研究

CPT-Pharmacometrics & Systems Pharmacology

IF3

2026-09-150

OAAI

Exposure-Response Relationships for Axatilimab in Patients with Chronic Graft-Versus-Host Disease

阿萨替利单抗在慢性移植物抗宿主病患者中的暴露-反应关系

Clinical Pharmacology & Therapeutics

IF5.5

2025-06-190

OA

An Integrative Mechanistic Model of Type 1 IFN-Mediated Inflammation in Systemic Lupus Erythematosus

系统性红斑狼疮中1型IFN介导炎症的整合机制模型

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2025-05-130

OA

Mathematical modeling in autoimmune diseases: from theory to clinical application (vol 15,1371620,2024)

FRONTIERS IN IMMUNOLOGY

IF5.9

2025-01-300

OAAI

Semimechanistic Population PK/PD Modeling of Axatilimab in Healthy Participants and Patients With Solid Tumors or Chronic Graft-Versus-Host Disease

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2024-12-200

OAAI

Mathematical modeling in autoimmune diseases: from theory to clinical application

FRONTIERS IN IMMUNOLOGY

IF5.9

2024-03-140

OAAI

A tutorial for model-based evaluation and translation of cardiovascular safety in preclinical trials

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2023-11-230

OAAI

Model-Based Assessment of the Reference Values of CAVI in Healthy Russian Population and Benchmarking With CAVI0

AMERICAN JOURNAL OF HYPERTENSION

IF3.1

2023-09-114

PRE

A mechanistic modeling platform of SGLT2 inhibition: Implications for type 1 diabetes

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2023-03-161

OAAI

Polymeric Nanoparticles with Embedded Eu(III) Complexes as Molecular Probes for Temperature Sensing

IF4.6

2022-12-125

OAAI

AZD8233 antisense oligonucleotide targeting PCSK9 does not prolong QT interval

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2022-06-1010

OAAI

Novel NIR-Phosphorescent Ir(III) Complexes: Synthesis, Characterization and Their Exploration as Lifetime-Based O2 Sensors in Living Cells

IF4.6

2022-05-1417

OAAI

Biocompatible Ir(III) Complexes as Oxygen Sensors for Phosphorescence Lifetime Imaging

IF4.6

2021-05-1320

OAAI

A model-based approach to investigating the relationship between glucose-insulin dynamics and dapagliflozin treatment effect in patients with type 2 diabetes

DIABETES OBESITY & METABOLISM

IF5.7

2021-01-256

PRE

Differentiating the Sodium-Glucose Cotransporter 1 Inhibition Capacity of Canagliflozin vs. Dapagliflozin and Empagliflozin Using Quantitative Systems Pharmacology Modeling

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2020-03-0631

OAAI

A Physiology-Based Model of rile Acid Distribution and Metabolism Under Healthy Pathologic Conditions in Human Beings

在人类健康病理条件下基于生理学的rile酸分布和代谢模型

CELLULAR AND MOLECULAR GASTROENTEROLOGY AND HEPATOLOGY

IF7.4

2020-01-0134

OAAI

Comparison of the urinary glucose excretion contributions of SGLT2 and SGLT1: A quantitative systems pharmacology analysis in healthy individuals and patients with type 2 diabetes treated with SGLT2 inhibitors

DIABETES OBESITY & METABOLISM

IF5.7

2019-09-0929

PREAI

Comparative quantitative systems pharmacology modeling of anti-PCSK9 therapeutic modalities in hypercholesterolemia[S]

JOURNAL OF LIPID RESEARCH

IF4.1

2019-09-0118

OAAI

Quantitative Systems Pharmacology: An Exemplar Model-Building Workflow With Applications in Cardiovascular, Metabolic, and Oncology Drug Development

CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY

IF3

2019-06-1144

OAAI

Urinary glucose excretion after dapagliflozin treatment: An exposure-response modelling comparison between Japanese and non-Japanese patients diagnosed with type 1 diabetes mellitus

DIABETES OBESITY & METABOLISM

IF5.7

2018-12-165

OAAI